Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-162-1 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental data investigating the toxicokinetic profile is available.
Based on the evidences from the toxicity studies no bioaccumulation potential can be derived.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Assessment on the toxicokinetic profile of the registration substance
No experimental data investigating the toxicokinetic property of the registration substance is available.
The assessment will be performed based on the following data:
- combined repeated dose toxicity with reproductive/developmental toxicity screening study on the read-across substance (Pentapropenyl succinimido)-hexanoate, sodium and triethanolamine salts
- 28-day study on the read-across substance (Tetrapropenyl succinimido)-caproic acid
- chemical structure and liphophilicity
- cytotoxicity data obtained in the preliminary studies in in-vitro genotoxicity on the read-across substance (Tetrapropenyl succinimido)-caproic acid
- BCF study in fish (endpoint study record provided in IUCLID chapter 5.3.1) on the read-across substance (Tetrapropenyl succinimido)-caproic acid
The justification for the read-across is provided in IUCLID chapter 13 and is not further mentioned here. The discussion will be focused on indications relevant for the bioaccumulating potential assessment of the registration substance.
Considering that the registration substance is soluble in octanol and is of molecular mass of resorption range (420 g/mol), it can be reasonably derived that the substance will be readily adsorbed and distributed via lymphatic tissues. The given LogPow > 3 is indicative that the elimination as unchanged molecule is not likely to occur. Two cases can be imagined: the degradation is not efficient and the internal burden increases with increasing exposure duration vs. the degradation is efficient and the internal burden is less dependent on the exposure duration. The second case would corresponds to “no bioaccumulating potential”.
The structural feature of N-alkylated imide in the center of molecule and highly branched alkenyl moiety imply a certain degree of resistance to undergo degradation process. A metabolic overload effect can be predicted in case of an extensive metabolism. In the available two mid-term studies, the liver was identified as the target organ and the observed alteration pattern of the findings (liver weight increase, hepatocellular hypotrophy, follicular cell hypotrophy in thyroid gland, prolonged bleeding time, altered values of glucose and cholesterols) were indicative of adaptation and/or metabolic overload. An extensive metaboliem can be derived.
It should be pointed out that the observed effects in liver disappeared completely within the recovery period of 14 days, indicating that the chemical burden must have decreased rapidly with the cessation of treatment. No bioaccumulating property for the registration substance can be derived.
Further support is given in the preliminary cytotoxicity study in in-vitro genotoxicity studies. The cytotoxicity with S9-mix was significantly reduced when compared to that of without S9-mix. The fact that the metabolic activation by action of liver enzymes is associated with detoxification implies that the liver is likely to serve as the detoxification organ under in-vivo condition.
Besides of toxicity studies, a no bioaccumulating potential/extensive metabolism can also be derived from the result obtained in the bioconcentration study in fish. The BCF in fish bioaccumulation study was< 158 at concentration of 0,06 mg/l. Assuming that the substance is readily bioavailable, and the LogPow is indicative of no elimination as unchanged molecule, the obtained low BCF value is demonstrative of an efficient elimination in fish.
Combining all the available evidences, it can be concluded that an extensive metabolism occurs in the liver. Based on the general rule of the biotransformation, the most likely degradation pathway is the ß-oxidation of N-alkyl chain, followed by the hydrolysis at the imine/imide moiety. The resulting metabolite, highly branched alkenyl-succinic acid, could undergo urinary excretion either as it is, or conjugated.
In conclusion, no bioaccumulating potential can be derived.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
